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Abstract
Aims: To systematically review the existing trials on optimal serum levels for lithium for 
maintenance treatment of bipolar disorder and to develop clinical recommendations.
Methods: Systematic literature search. Discussion of major characteristics, limita‐
tions, methodological quality, and results of selected trials. Delphi survey consisting 
of clinical questions and corresponding statements. For statements endorsed by at 
least 80% of the members, consensus was considered as having been achieved.
Results: With strict inclusion criteria no studies could be selected, making it difficult 
to formulate evidence‐based recommendations. After loosening the inclusion crite‐
ria 7 trials were selected addressing our aims at least to some extent. Four of these 
studies suggest better efficacy being associated with lithium serum levels in a range 
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1  | INTRODUC TION
Lithium has been licensed in Europe and North America for the long‐
term maintenance treatment of bipolar disorder (BD) for more than 
45 years and is justifiably considered one of the first line options in 
major global treatment guidelines, such as the WFSBP guideline,1 the 
NICE guideline,2 the RANZCP guideline,3 the Dutch guideline,4 the 
BAP guideline,5 the CINP guideline6 and the CANMAT/ISBD guide‐
line.7 However, lithium has a very low therapeutic index, that is, a low 
ratio between the dose (or serum level) that is associated with toxicity 
(mainly CNS and renal toxicity) and the dose associated with thera‐
peutic effect. The therapeutic index for lithium is approximately 2.8
For maintenance treatment of BD several reviews recommend 
differing minimum effective lithium serum levels ranging from 
0.40 mmol/L9‐11 and 0.50 mmol/L,12 or 0.60 mmol/L 13 to as high as 
0.80 mmol/L.14,15 In addition, some major clinical practice guidelines 
recommend optimal ranges, but these also lack consistency. For in‐
stance, the NICE guideline,2 the RANZCP guideline 3,16 and the BAP 
guideline 5 recommend 0.60‐0.80 mmol, the CANMAT/ISBD guide‐
line 7 0.60‐1.00 mmol/L, and the CINP guideline 6 0.60‐1.20 mmol/L, 
whereas other guidelines, for example, the WFSBP guideline,1 do 
not provide specific recommendations. Finally, some reviews more 
specifically recommend targeting serum levels for individual pa‐
tients “on the basis of efficacy and tolerability” without further specifi‐
cation15 or “primarily at 0.60‐0.75/0.80 guided by clinical response and 
tolerability” 16 within a broad range of 0.40‐1.20 mmol/L,10 which is 
also recommended in the Dutch guideline.4 The major problem un‐
derlying these different recommendations is that large studies, well 
designed to assess the optimal serum level in maintenance treat‐
ment, specifically the serum level that best balances efficacy and 
tolerability for most patients, are lacking.
In clinical pharmacology recommendations for the optimal dose 
(or serum level) of a drug should be based on studies in which patients 
are randomized to different groups with various a priori defined fixed 
doses/serum levels (or narrow dose/serum level ranges) of the drug 
in question. This is necessary as in studies with flexible doses/serum 
levels or with wide dose/serum level ranges, prescribers are inclined 
to increase the dose/serum level especially in those patients who are 
not responding to (and are tolerating) the original dose/serum level, 
resulting in a so called channeling effect: nonresponding patients 
are treated with higher doses/serum levels than patients who have 
already responded to lower doses/serum levels17 or dosing following 
outcome rather than outcome following dose.18
To our knowledge, the most recent systematic review on opti‐
mal serum levels for lithium in the maintenance treatment of BD by 
Severus et al10 identified only 5 studies that addressed this issue, 
most with small samples sizes. A further limitation of this review 
is that several important methodological aspects and limitations 
of the studies were discussed only briefly. Moreover, many clinical 
questions have not been systematically addressed in the literature, 
for example, what is the best timing of blood sampling? Should the 
recommendations be different for dosing once daily vs twice daily? 
Should the recommendations be different for immediate release vs 
extended release formulations? Should the optimal serum level be 
different for the prevention of manic (and mixed) episodes compared 
to depressive episodes? Should recommendations take ethnicity/
race or gender into consideration? And should recommendations for 
children and adolescents or for elderly patients be different from the 
recommendations for nonelderly adults?
Based on the need for an updated and more critical systematic re‐
view of the literature on optimal serum levels for lithium in the mainte‐
nance treatment of BD, a joint International Society for Bipolar Disorders 
(ISBD) and International Study Group on Lithium (IGSLI) Task Force on 
the Treatment with Lithium was charged to address this topic (and other 
lithium related topics). In addition, it was decided to develop a consensus 
on recommendations for optimal serum levels that also attempted to an‐
swer key clinical questions such as those outlined above, for which there 
apparently was no direct evidence available, using the Delphi method.
above a lower threshold around 0.45/0.60 and up to 0.80/1.00 mmol/L. These find‐
ings support the outcome of the Delphi survey.
Conclusions: For adults with bipolar disorder there was consensus that the stand‐
ard lithium serum level should be 0.60‐0.80 mmol/L with the option to reduce it 
to 0.40‐0.60 mmol/L in case of good response but poor tolerance or to increase it 
to 0.80‐1.00 mmol/L in case of insufficient response and good tolerance. For chil‐
dren and adolescents there was no consensus, but the majority of the members 
endorsed the same recommendation. For the elderly there was also no consensus, 
but the majority of the members endorsed a more conservative approach: usually 
0.40‐0.60 mmol/L, with the option to go to maximally 0.70 or 0.80 mmol/L at ages 
65‐79 years, and to maximally 0.70 mmol/L over age 80 years.
K E Y W O R D S
bipolar disorder, Lithium, maintenance treatment, serum level
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2  | METHOD
2.1 | Composition of the task force
The ISBD/IGSLI Task Force on Lithium (further Task Force) was 
comprised of global experts active in ISBD or IGSLI and further‐
more selected on their contributions to the literature on lithium. 
The Task Force started at the annual conference of the ISBD in 
Seoul (2014) while a subgroup of the Task Force (WN, ES, RL, 
GM, AY, MT) initiated this project on optimal serum levels for 
lithium at the annual ISBD conference in Washington (2017) and 
further discussed it at the annual ISBD conference in Mexico City 
(2018).
2.2 | Selection of literature
As a first step 2 members of the Task Force (WN and ES on August 
28, 2017) initiated a systematic literature search in PubMed with 
the following search terms limited to “clinical trials” and “reviews”: 
“lithium” and “bipolar disorder” and [“serum level” or “serum con‐
centration” or “plasma level” or “plasma concentration” or “blood 
level” or “blood concentration” or “lithium level” or “lithium 
concentration”].
From the retrieved trials we initially intended to examine and 
discuss only those which fulfilled a priori defined inclusion criteria 
(see Table 1). The included trials were rated for their methodological 
quality regarding randomization, blinding and description of with‐
drawals, and dropouts ensuring intent to treat analysis, according to 
the Jadad Scale19 as poor (score 0‐2), moderate (score 3‐4), or good 
(score 5).
2.3 | Delphi method
Anticipating that our literature review would fall short of providing 
clear evidence‐based conclusions and definite guidance regarding 
optimal lithium serum levels, we concurrently developed a survey 
consisting of clinical questions and corresponding statements using 
the Delphi method.20 Informed by the findings of clinical trials that 
have been conducted and by existing reviews and guidelines we for‐
mulated 32 statements on 16 clinical questions (see Supplemental 
Table S1) presented to all 50 Task Force members, representing 15 
countries. They were asked to score all statements as “Agree” or 
“Not agree”, with the option in several statements to mark a pre‐
ferred additional more specified response. For statements endorsed 
by at least 80% of the participating members consensus was consid‐
ered as having been achieved.
Two survey rounds were initially planned. In the first survey 
round we tested the statements and besides asking members to 
choose among the additional responses, we also asked for com‐
ments on the statements and on the additional responses. After 
having received the responses and comments it was concluded that 
a second survey round was not needed as the comments received 
did not reveal a need to change statements or responses.
2.4 | Further procedure
The subgroup that initiated this project consisted of WN, ES, RL, 
GM, AY, and MT. Selection of studies and data extraction was con‐
ducted by WN and ES. The first drafts of the paper and the Delphi 
statements were written by WN in collaboration with ES and RL and 
# Original inclusion criteria Modified inclusion criteria
1 Patients with BD, either type 1 or type 2 or 
both or unspecified. In instances where the 
trial also included other patient groups, the 
results of BD patients had to have been re‐
ported separately, or at least 80% of the total 
group should comprise BD patients
Also allowing studies with patients 
with recurrent mood disorder, 
with at least some specified out‐
come data on patients with BD
2 Patients to be currently in remission Also allowing studies with patients 
not in remission
3 Maintenance treatment with lithium aimed 
at preventing a new (treatment emergent) 
episode
Also allowing studies with lithium 
being used in the long‐term treat‐
ment, ie in studies with a follow‐
up of at least 3 months
4 Evaluated the efficacy of lithium as 
monotherapy
Also allowing studies with lithium 
given in combination with other 
psychotropic drugs
5 Had a randomized controlled design Also allowing non‐randomized 
controlled studies under the 
condition of no clear indication of 
channeling bias
6 Patients were assigned to groups with differ‐
ent treatment regimens with lithium resulting 
in different a priori defined fixed lithium 
serum level ranges
Also allowing studies comparing 
different fixed lithium serum level 
ranges, but not a priori defined
TA B L E  1   Overview of original 
inclusion criteria (see method) and 
modified inclusion criteria (see results)
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then circulated for comments and suggestions to GM, AY, and MT 
resulting in a second draft that was sent to all Task Force members 
for comments and/or discussion at (or prior to) the annual ISBD con‐
ference in Mexico City (2018). This resulted in a third draft of the 
paper (including introduction, the method section, and results from 
the systematic review but still without the results of the Delphi sur‐
vey and the discussion section) that was developed in the same way 
and again send to all members together with the first round of the 
Delphi survey.
With the results of the Delphi survey a fourth complete draft 
(now also with the discussion section) was again written by WN, ES, 
RL, GM, AY, and MT, and then sent to all Task Force members for 
comments and approval. As last step the final version was send for 
final approval to all authors (now also including EV, RK, CZ, RN, and 
RB), while those Task Force members who at least had completed 
the Delphi survey and approved the manuscript were listed as mem‐
bers of the Task Force.
After having received the reviewers’ comments, the definite text 
was written by WN, ES, RL, GM, AY, and MT.
3  | RESULTS
3.1 | Selection of literature
The results of our literature search and the further selection is pre‐
sented in Figure 1.
The literature search in PubMed resulted in 128 trials and 204 
reviews, of which we based on the abstracts selected 7 trials and 5 
reviews for full‐text reading. In addition, we added another 12 pa‐
pers from reference lists of the selected papers and already known 
to us: 9 trials and 3 reviews.
In the first instance we excluded all 16 selected trials, as none 
of the trials fulfilled all 6 inclusion criteria (see above). However, we 
then decided to modify the inclusion criteria by loosening them (see 
again Table 1).
After this adjustment 7 trials could be included; in chronological 
order: Jerram & McDonald21 (further Jerram); Waters et al22 (further 
Waters); Coppen et al23 (further Coppen); Maj et al24 (further Maj); 
Gelenberg et al25 (further Gelenberg); Vestergaard et al26 (further 
Vestergaard); and Nolen & Weisler27 (further Nolen). Nine other tri‐
als remained excluded on the following basis: because of possible 
channeling bias,28‐31 reporting duplicate information,32,33 post‐hoc 
analyses of original studies with potential channeling bias34,35 or ad‐
dressing a different question.36
In addition, 8 literature reviews were selected: Sashidharan9; 
Hopkins & Gelenberg13; McIntyre et al14; Sproule15; Severus et al37; 
Severus et al10; Wijeratne & Draper12; and Dols et al.38
3.2 | Description of the included trials
Jerram21 included “just over 80” patients with bipolar (BP) or unipolar 
depressive (UP) disorder, of whom 51 BP (and 22 UP) patients com‐
pleted the one year study, indicating that about 10 BP or UP patients 
dropped out. At baseline, all patients were in remission and using 
lithium while potential use of other psychotropic medication is not 
reported. Patients were randomized to 3 different a priori defined 
12‐hour lithium level ranges: <0.50; 0.50‐0.69, and ≥0.70 mmol/L. 
Endpoint was “need for additional psychotropic medication and/or 
admission”.
Thus, this study fulfilled 4 of the 6 original inclusion criteria (2, 
3, 5, and 6). Other limitations are that the minimum and maximum 
lithium levels were not defined for the lower and upper lithium level 
ranges respectively, that the randomization procedure is unclear, 
that the study was not blind, that blood was collected between 12 
and 16 hours after the last intake and that only the number of BP 
patients who completed the study is presented, leaving unclear how 
many BP patients were included and how many dropped out.
Waters22 included 36 BP patients of who 29 completed the 1 
year study. It is uncertain whether patients were in remission, as 
they “had to have reported residual endogenous mood swings which 
F I G U R E  1   Prisma flow diagram of the 
selection of papers [Colour figure can be 
viewed at wileyonlinelibrary.com]
Papers excluded on abstract: n = 320
- Other aim of the trial: n = 121
- Other topic of the review: n = 199
Additionally identified
papers: n = 12
- Trials: n = 9
- Reviews: n = 3
Full-text papers assessed
for eligibility: n = 24
- Trials: n = 16
- Reviews: n = 8
In first instance excluded trials: n = 16
- Not fullfilling inclusion criteria: n = 13
- Duplicates: n = 3
Included trials: n = 7
Included reviews: n = 8
In second instance included trials: n = 7 
- Fullfilling loosened criteria: n = 7
Included papers: n = 8
- Trials: n = 0
- Reviews: n = 8
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had not required hospitalization” in the past 2 years, indicating that 
this study was not a pure recurrence prevention study. At baseline 
randomization all were using lithium while potential use of other 
psychotropic medication is not reported. Patients were randomized 
to 2 different a priori defined lithium level ranges: 0.30‐0.80 and 
0.80‐1.40 mmol/L. Endpoint was “change in mood of a sufficient de‐
gree to require clinically additional pharmacological intervention […]”.
Thus, this study fulfilled only 3 of the original inclusion criteria (1, 
5, and 6). Further limitations are that the timing of blood collection 
was not reported and that the procedure used for randomization is 
unclear.
Coppen23 included 88 BP and UP patients of whom 72 com‐
pleted the 1 year study, including 23 BP patients. Prior to the trial 
all patients already were using lithium with a mean serum level of 
0.86 ± 0.20 mmol/L, and an unreported number were also using anti‐
psychotics or antidepressants. The patients were probably also not in 
remission as the report presents pre‐trial morbidity data which were 
compared with data during the trial, implying that it was not a pure 
recurrence prevention study. At baseline patients were randomized 
to continue lithium at the same dose or to receive a dose reduction in 
about 25% or 50% resulting in 3 different 12‐hour lithium level ranges 
of 0.45‐0.59, 0.60‐0.79, and ≥0.80 mmol/L. Outcome measure was 
not a relapse or recurrence but the change in score on the Affective 
Morbidity Index during the trial compared to pre‐trial ratings.
Thus, this study only fulfilled 2 of the original inclusion criteria (5 
and 6). Further limitations are that only the number of BP patients 
who completed the study is presented, leaving unclear how many 
BP patients were included and how many dropped out and that the 
randomization procedure is unclear.
Maj24 studied 80 BP patients (69 completers) with recurrent ep‐
isodes (at least one episode during the 2 years “preceding the index 
episode and the commencement of lithium prophylaxis”), indicating 
that patients were not in remission (implying that it was not a pure 
recurrence prevention study), but also leaving unclear whether or 
not patients were already using lithium prior to the trial. At baseline, 
patients were divided (but not randomized, personal information to 
ES) to 4 different groups (n = 20) with 12‐hour lithium levels ranges 
of 0.30‐0.45, 0.46‐0.60, 0.61‐0.75, and 0.76‐0.90 mmol/L, while po‐
tential use of other psychotropic medication is not reported. Major 
endpoint was “mean number of episodes and mean total morbidity (ex‐
pressed in months)” during the 2 years of the trial compared with the 
2 years prior to the trial.
Thus, this study only fulfilled 2 of the original inclusion criteria (1 
and 6). Another limitation is that the study was not blind.
Gelenberg25 studied 94 BP‐1 patients of whom 59 completed 
the 3‐year trial. All patients had to be stable for at least 2 months 
since the last episode and also at least 2 months tolerating lithium 
at serum level 0.60‐1.00 mmol/L, while potential use of other psy‐
chotropic medication at start or during the trial is not reported. At 
baseline patient was randomized to 2 different a priori defined lith‐
ium level ranges: 0.40‐0.60 and 0.80‐1.00 mmol/L. Endpoint was a 
recurrence of mania or major depression, defined by DSM‐III or RDC 
criteria.
Thus, this study fulfilled 5 of the original inclusion criteria (1, 2, 
3, 5, and 6). A source of bias could be the abrupt lowering of the lith‐
ium levels at randomization in patients previously responding to high 
levels resulting in a risk of drug‐discontinuation related morbidity.34 
Another limitation is that only the patients but not the investigators/
clinicians were blind to the dosage‐assignment.
Vestergaard26 included 57 BP and 34 UP patients in a 2‐year 
follow‐up trial. At baseline all patients were still hospitalized (in‐
dicating that they were not in remission and implying that it was 
not a real recurrence prevention study) and about half of them 
were still using antipsychotics or antidepressants. Whether (some) 
patients were also already using lithium remains unclear in the 
report. At baseline patients were randomized double blind to 2 
different a priori defined lithium level ranges of 0.50‐0.80 and 
0.80‐1.00 mmol/L. Endpoint was recurrence (or relapse) defined 
as “re‐emergence of affective disorder of a severity that rendered re‐
hospitalization necessary”.
Thus, this study fulfilled only 2 of the original inclusion criteria 
(5 and 6). Further limitations are that the study was not blind and 
that only the number of BP patients who were included is presented, 
leaving unclear how many BP patients completed the study and how 
many dropped out.
Nolen27 published a post‐hoc analysis of a long‐term study in‐
tended to test the efficacy of quetiapine.39 In this study patients with 
BP‐1 disorder with a recent manic of depressive episode who had 
achieved remission during ≥4 weeks of open‐label treatment with 
quetiapine monotherapy were randomized to 2‐years treatment of 
continued quetiapine or switch to placebo or lithium. According to the 
protocol, the 418 patients in the lithium arm should have received a 
lithium dose resulting in a 12‐hour lithium level of 0.60‐1.20 mmol/L, 
guided by a “programmed automatic system” to alert treating clinicians 
to adjust dose while maintain blind to the drug (lithium, quetiapine 
or placebo). However, in 54 patients no blood levels were measured 
while in 137 patients mean lithium levels remained below the min‐
imum predefined level of 0.60 mmol/L, probably due to a failure of 
the programmed automatic system to adjust the dose, rather than 
due to adverse events or early response (being the most important 
indicators of channeling). This circumstance created the possibility to 
compare these 137 patients with the 201 patients receiving lithium 
within the predefined range of 0.60‐1.20 mmol/L and with the pa‐
tients receiving placebo (n = 404). Endpoint was a recurrence defined 
as the “initiation of [psychotropic medication] to treat a mood event, hos‐
pitalization for a mood event, or a YMRS or MADRS score of ≥20”.
Thus, this study fulfilled 4 of the original inclusion criteria (1, 2, 
3, and 4). Besides that the composition of both lithium arms was not 
the result of randomization and the levels were not a priori defined, 
another major limitation of this study is that it was discontinued pre‐
maturely by the sponsor after an interim analysis after 300 mood 
events had revealed superiority of quetiapine over placebo, which 
resulted in loss of probably 15%‐20% of patients before completing 
the 2‐year follow‐up. Finally, although called a “trough” level, it is un‐
clear form the paper whether blood was sampled after 12 ± 1 hour 
after the last evening intake.
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In summary, none of the 7 trial studies described above fulfilled 
all original inclusion criteria (Table 2). Four studies (Waters, Maj, 
Gelenberg, Nolen) addressed only BP patients (original criterion 
1) and the remaining 3 studies (Jerram, Coppen, Vestergaard) in‐
cluded both BP and UP patients without a complete description 
of the results in de BP patients. Three studies (Jerram, Gelenberg, 
Nolen) included only patients who were in remission (original cri‐
terion 2) and so were pure recurrence prevention studies (original 
criterion 3), whilst the other 4 studies included patients with “re‐
sidual mood swings” (Waters), who were hospitalized (Vestergaard) 
or included patients with morbidity (Coppen, Maj) and thus also 
examined the direct/acute effects. Only 1 study (Nolen) investi‐
gated solely the effect of lithium as monotherapy (original criterion 
4), 2 studies (Coppen, Vestergaard) reported that at least some 
patients used antipsychotics and/or antidepressants, and 4 stud‐
ies (Jerram, Waters, Maj, Gelenberg) did not provide information 
on (possible) use of concurrent medication. Five studies (Jerram, 
Waters, Coppen, Gelenberg, Vestergaard) were randomized (origi‐
nal criterion 5), implying that lithium level ranges were not affected 
by channeling, while the remaining 2 studies (Maj, Nolen) were not 
randomized, but it is likely that the composition of the different lith‐
ium groups in these studies was not affected by channeling (see also 
below). Finally, 6 studies (Jerram, Waters, Coppen, Maj, Gelenberg, 
Vestergaard) compared a priori defined lithium level ranges (original 
criterion 6), while the seventh study (Nolen) involved 2 groups with 
lithium level ranges defined post‐hoc, as well as a group receiving 
placebo.
Table 3 provides information on prior treatment with lithium; 
treatment at randomization; details regarding treatment with lith‐
ium; and treatment with other psychotropic medication at fol‐
low‐up. No study provided adequate information on all potentially 
relevant points. It illustrates the heterogeneity of the included 
studies.
3.3 | Quality assessment of the included studies
Regarding JADAD criteria to rate methodological quality, 5 of the 
7 studies involved randomized assignment to particular serum con‐
centrations of lithium. However, the randomization was described 
adequately in only studies (Gelenberg, Vestergaard) and not in the 
remaining 3 studies (Jerram, Waters, Coppen); 2 studies were not 
randomized (Maj, Nolen). Three studies had a double‐blind design, 
which was well described in 1 study (Nolen) but not in the other 
2 studies (Waters, Coppen); 1 study was blind for patients but 
not for investigators/clinicians (Gelenberg); 3 studies were open 
(Jerram, Maj, Vestergaard). Finally, 4 studies adequately reported 
the number and reasons for drop‐outs (Waters, Maj, Gelenberg, 
and Nolen), but the remaining 3 studies did not (Jerram, Coppen, 
Vestergaard).
Consequently, the JADAD quality scores for the included studies 
varied from low, that is, score 1 (Jerram, Maj) or 2 (Waters, Coppen, 
Vestergaard) to moderate, that is, score 3 (Gelenberg, Nolen). No 
study received score 4 or the highest score 5.
3.4 | Clinical outcomes of the included studies
Table 4 summarizes the most important clinical outcomes of the in‐
cluded studies. Significant differences between lithium serum level 
ranges are indicated by green (better outcomes) vs red (poorer out‐
comes), while outcomes which were not significantly different are 
indicated by blue.
The findings of the 7 studies are summarized in Table 4. Taken to‐
gether, 4 studies (Waters, Maj, Gelenberg, and Nolen) indicate bet‐
ter long‐term efficacy in the prevention of any mood episode with 
mean lithium serum levels in a range above a lower threshold around 
0.45/0.60 and up to 0.80/1.00 mmol/L. The other 3 studies (Jerram, 
Coppen, Vestergaard) did not find a significant difference between 
higher vs lower lithium levels.
In addition, 4 studies also looked at possible differences be‐
tween the prevention of manic vs depressive recurrences. Only 
1 study (Maj) suggested a lower threshold for the prevention 
of manic symptoms (around 0.45 mmol/L) than for depressive 
symptoms (around 0.60 mmol/L). Another study (Nolen) suggests 
the same threshold of 0.60 mmol/L for both the prevention of 
manic and depressive recurrences. The other 2 studies (Waters, 
Vestergaard) also found no difference in polarity of response and 
lithium levels.
Finally, 3 studies, addressed the association of lithium levels with 
adverse effects. Two studies, reported more side effects with levels 
0.45‐0.60 and higher vs 0.30‐0‐45 (Maj) and with levels 0.80‐1.00 vs 
0.40‐0.60 (Gelenberg), while the third study (Nolen) did not report 
different drop‐outs rates due to side effects between the 3 groups 
(lithium <0.60 mmol/L, lithium 0.60‐1.20 mmol/L and placebo).
3.5 | Delphi survey
The Delphi survey was completed by 33 of the 50 (66.6%) Task 
Force members. Many statements received additional comments, 
most frequently that evidence regarding a statement or a specified 
response was lacking.
There was consensus on recommendations regarding timing 
of blood sampling to measure lithium serum levels during the day 
and on whether recommendations for optimal serum lithium levels 
should be the same with once daily dosing compared to twice daily 
dosing, as well as with different formulations of lithium medication 
(immediate release vs extended release).
There was a lack of consensus on the overall statement “The 
higher the lithium serum level, the higher the likelihood of a preventa‐
tive response” (endorsed by only 54.5%) while several members com‐
mented that serum levels in the lower range (below 0.60 mmol/L) are 
associated with efficacy but in the higher range (above 1.00 mmol/L) 
with more adverse effects and toxicity. In addition, there was no con‐
sensus on the statement “There is a minimum serum cut‐off level below 
which essentially no patients are likely to experience a preventative ef‐
fect” (endorsed by 72.7%) while there was a wide range of specified 
responses regarding for a specific cut‐off level (0.30, 0.40, 0.50, or 
0.60 mmol/L, endorsed by 16.7, 41.7, 16.7, or 20.8%, respectively). In 
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contrast, there was consensus on the statement “There is a maximum 
lithium serum level that should ideally never be exceeded because of the 
risk of severe intolerance and/or intoxication” (endorsed by 93.9%) but 
lack of agreement on a specific upper limit to recommend: most fre‐
quently supported limits being 1.00 and 1.20 mmol/L, endorsed by 
35.5 and 38.7%, respectively.
The major recommendations including 7 statements endorsed by 
at least 80% of the members (consensus) are summarized in Table 5.
Regarding recommended standard lithium serum levels in the 
maintenance treatment there was only consensus on the recom‐
mendation for adults, but not for children <12 years, adolescents 
12‐17 years, the elderly 65‐79 and the elderly ≥80 years. However, 
the most frequently endorsed minimum level was 0.40 mmol/L 
for all age groups, whereas the maximum level varied with age; 
1.00 mmol/L for adults, children and adolescents and between 0.70 
and 1.00 mmol/L for the elderly.
Finally, for the prevention of specific episodes there was con‐
sensus for recommending similar levels for the prevention of mixed 
episodes vs manic episodes (endorsed by 87.9%) but not for recom‐
mending similar levels for the prevention of manic vs depressive 
episodes and for the prevention of hypomanic or subthreshold de‐
pressive episodes vs manic and depressive episodes, respectively.
4  | DISCUSSION
The key conclusion from this review (and the major limitation) is that 
there is a lack of well‐designed, double‐blind randomized dose find‐
ing (or serum level finding) studies assessing optimal lithium serum 
level in the maintenance treatment of BP. This conclusion is truly 
remarkable given that lithium has been available for the treatment 
of BP since it was licensed in the early 1970s. This paucity of data 
makes it difficult if not impossible to formulate confident evidence‐
based recommendations for the dosing of lithium based on moni‐
toring its serum level. Based on the initial inclusion criteria for our 
systematic review we were unable to identify any study that fulfilled 
all 6 original inclusion criteria for our review. Only after loosening 
these criteria, we identified 7 studies that addressed, at least to 
some extent, the questions we posed at the outset, and outlined in 
the introduction.
4.1 | Selection of studies
A major issue in the selection of studies was that we wanted to 
compare similar groups of patients treated with lithium at different 
serum levels while the composition of the groups should not be in‐
fluenced by channeling of nonresponding patients with good toler‐
ance to higher lithium level groups and early responding patients or 
patients with low tolerance to lower lithium level groups. Therefore, 
we initially intended to select only studies with a randomized design 
(criterion 5) in which patients were assigned to different treatment 
regimens with lithium resulting in different a priori defined fixed 
lithium serum level ranges (criterion 6). Five studies (Jerram, Waters, T
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TA B L E  5   Recommendations from the Delphi survey regarding lithium serum levels in the maintenance treatment of bipolar disorder 
endorsed by at least 80% (consensus) of the participating members of the task force, or by less than 80% (no consensus)
Domain Recommendation
Timing of blood sampling to 
measure lithium serum levels
            Consensus
 1 With twice daily dosing: sampling should be in the morning 12 ± 1 hours after 
intake of the (last) evening dose and before the morning dose (endorsed by 
93.5%)
 2 With once daily dosing in the evening: sampling should be in the morning, 
12 + 1 hours after intake of the (single) evening dose (endorsed by 93.5%)
             No consensus
 ‐ With once daily dosing in the morning: sampling should be in the evening, 
12 ± 1 hours after intake of the (single) morning dose (endorsed by 74.2%)
Once daily dosing vs twice daily 
dosing
           Consensus
 3 The recommendations for optimal serum lithium levels with once daily dosing 
of lithium should be the same as compared to twice daily dosing (endorsed 
by 90.9%)
Immediate release formula vs 
extended release formulations
           Consensus
 4 The recommendations for optimal serum lithium levels with immediate 
release formulations should be the same as compared to extended release 
formulations (endorsed by 93.9%)
Maximum lithium serum level           Consensus
 5 There is a maximum serum lithium level that should ideally never be exceeded 
because of the risk of severe intolerance and/or intoxication (endorsed by 
93.9%)
           No consensus On specific maximum level
 ‐ Most frequently mentioned: 1.00 mmol/L (endorsed by 35.5%) and 
1.20 mmol/L (endorsed by 38.7%)
Recommendations for optimal 
serum lithium levels in differ‐
ent age groups
          Consensus
 6 For adults (18‐65 y): 
The standard serum level should be 0.60‐0.80 mmol/L with the option to re‐
duce the level to 0.40‐0.60 mmol/L in case of poor tolerance or to increase 
the level to 0.80‐1.00 mmol/L in case of insufficient response (endorsed by 
93.9)
            No consensus
 ‐ For children (<12 y): 
The standard level should be 0.60‐0.80 mmol/L, with the option to 
reduce the level to 0.40‐0.60 mmol/L in case of poor tolerance or to 
increase the level to 0.80‐1.00 mmol/L in case of insufficient response 
(endorsed by 57.6%)
 ‐ For adolescents (12‐17 y): 
The standard level should be 0.60‐0.80 mmol/L, with the option to 
reduce the level to 0.40‐0.60 mmol/L in case of poor tolerance or to 
increase the level to 0.80‐1.00 mmol/L in case of insufficient response 
(endorsed by 75.8%)
 ‐ For the elderly (65‐79 y): 
The standard serum lithium level should be 0.40 ‐ 0.60 mmol/L, with the op‐
tion to increase to 0.60 ‐ 0.80 mmol/L or to even 0.80 −1.00 mmol/L in case 
of insufficient response (unless there are somatic contra‐indications and 
with close monitoring of emergent side effects) (endorsed by 63.6%)
(Continues)
404  |     NOLEN Et aL.
Coppen, Gelenberg, Vestergaard) were randomized. The remaining 
2 studies (Maj, Nolen) were not randomized, but it is likely that the 
composition of the different lithium groups in these studies was not 
seriously affected by channeling. In the Maj study the patients were 
allocated in an open way to 4 different groups at baseline, while in 
the Nolen study due to an organizational failure (see above) a large 
group of patients remained below the predefined minimum level of 
0.60 mmol/L, resulting in the possibility to compare 2 groups below 
or above this level.
Nevertheless, prior to start of follow‐up some channeling may 
have occurred in the pre‐randomization open treatment phase in 
which all patients (Jerram, Waters, Coppen, Gelenberg) or possibly 
some patients (Vestergaard) were already using lithium. In particular, 
if lithium had been given prophylactically with at least some suc‐
cess regarding efficacy and tolerability (Jerram, Waters, Coppen) the 
probability that relevant channeling with regard to the topic of the 
trial, namely the prophylactic efficacy of lithium, may have occurred, 
cannot be dismissed. Similarly, an unknown number of patients in 
the Maj study were already using lithium prior to allocation to one of 
the groups/start of follow‐up. This may have resulted in these stud‐
ies in some selection bias: of poorer responding and better tolerating 
patients in the groups with higher lithium serum levels. In fact, the 
only study in which we can be confident that channeling did not hap‐
pen regarding lithium levels prior to start of follow‐up, is the (non‐
randomized) study by Nolen, as this is the only study where patients 
were not already using lithium at start of follow‐up.
An example of the excluded studies is the study by Tohen et 
al31 which compared in a randomized controlled, double‐blind de‐
sign 2 groups of patients treated with olanzapine or lithium mono‐
therapy after an open label phase in which they were treated for 
a manic episode with the combination of olanzapine and lithium. 
During the open label phase, lithium serum levels were targeted at 
0.60‐1.20 mmol/L, depending on overall response to and tolerance 
of the combination. Only responders were randomized to the double 
blind maintenance phase (enriched sampling). However, some pa‐
tients remained below 0.60 mmol/L, for instance when they did not 
tolerate lithium (combined with olanzapine) at the intended level. In 
a post‐hoc analysis of this study by Severus et al35 3 subgroups were 
compared within the group randomized to continuing lithium at the 
same level as in the open treatment phase (<0.60, 0.60‐0.79 and 
≥0.80 mmol/L). Although the original study protocol (31) prevented 
channeling in the double blind phase, channeling could have oc‐
curred during the open label phase as some patient had levels lower 
than 0.60 mmol/L and no new groups were constructed at the start 
of follow‐up in the original study. Thus, the design differed from the 
Maj study that did not include an acute phase while most patients 
were allocated open label to different lithium levels from the start 
of treatment with lithium, and from the Nolen study (see above). 
However, as the post‐hoc analysis (35) used proportional hazards 
Cox regression models and marginal structural models (MSMs) con‐
trolling for, among other variables, olanzapine and lithium dose at 
randomization as well as variables related to the disease severity 
Domain Recommendation
 – For the elderly (80 y and older): 
The standard serum lithium level should be 0.40 ‐ 0.60 mmol/L, with the 
option to increase to 0.60 ‐ 0.70 mmol/L (and not higher) in case of insuf‐
ficient response (unless there are somatic contra‐indications and with close 
monitoring of emergent side effects) (endorsed by 48.5%) 
 ‐ The standard serum lithium level should be 0.40 ‐ 0.60 mmol/L, with the 
option to increase to 0.60 ‐ 0.80 mmol/L (and not higher) in case of insuf‐
ficient response (unless there are somatic contra‐indications and with close 
monitoring of emergent side effects) (endorsed by 48.5%)
Optimal lithium serum levels 
for the prevention of specific 
episodes
           Consensus
 7 The recommendations for the prevention of episodes of mania or depression 
with mixed features should be the same as the recommendations to prevent 
manic recurrences (endorsed by 87.9%)
             No consensus
 ‐ The recommendations for the prevention of manic recurrences should be the 
same as the recommendations to prevent depressive recurrences (endorsed 
by 66.7%)
 ‐ The recommendations for the prevention of hypomanic recurrences should 
be the same as the recommendations to prevent manic recurrences (en‐
dorsed by 78.8%)
 ‐ The recommendations for the prevention of subsyndromal depressive recur‐
rences should be the same as the recommendations to prevent depressive 
recurrences (endorsed by 78.8%)
TA B L E  5   (Continued)
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and index episode features at baseline as well as variables related to 
the previous course of illness, the significance of the results of this 
post‐hoc analysis may in fact be comparable to those of a random‐
ized controlled trial.
4.2 | What is the optimal serum level for lithium 
in the maintenance treatment of bipolar disorder?
The main finding of our review is that 4 of the 7 included stud‐
ies reported significantly fewer recurrences with lithium levels 
0.80‐1.40 mmol/L vs 0.30‐0.80 (Waters); 0.61‐0.90 vs 030‐0.45 
(Maj); 0.80‐1.00 vs 0.40‐0.60 (Gelenberg); and 0.60‐1.00 vs 
<0.60 mmol/L (Nolen). In addition, the latter study found superior‐
ity of 0.60‐1.20 vs placebo but not of <0.60 vs placebo. Taken to‐
gether, these studies suggest better efficacy being associated with 
lithium levels in a therapeutic range with a lower threshold around 
0.45/0.60 and up to 0.80/1.00 mmol/L. The other 3 studies (Jerram, 
Coppen, Vestergaard) did not find a significant difference between 
higher vs lower lithium levels.
There is also some additional information from some of the 
above studies. Hullin40 performed a further second year follow‐up 
of Jerram study of the combined group patients (n = 68) with BP 
or UP. In this second year 5/28 patients (17.8%) with lithium levels 
of 0.60‐1.00 mmol/L and 4/27 patients (14.8%) of those with levels 
between 0.40 and 0.59 had a recurrence. In contrast, in the group 
maintained on lithium levels between 0.25 and 0.39 mmol/L, 8/13 
patients (61.5%) had a recurrence. Despite that no separate results 
were presented for the BP sample, this finding suggests that the 
cutoff for an effective lithium level may be around 0.40 mmol/L. In 
contrast however, a further subdivision of the 2 lithium groups in the 
Nolen study revealed that the Hazard ratio's (HR) vs placebo were 
not significant for lithium <0.40 mmol/L (HR 0.66; 95% CI: 0.42‐1.03) 
and 0.40 to <0.60 mmol/L (HR 1.05; CI: 0.67‐1.63) while they were 
significant for lithium 0.60 to <0.80 (HR 0.35; CI: O.23‐0.52) and 
0.80 to <1.00 (HR 0.24; CI: 0.14‐0.42), but not for lithium 1.00‐1.20 
(HR 0.50; CI: 0.21‐1.22). These findings suggest that the cutoff is 
more likely to be around 0.60 mmol/L than around 0.40 mmol/L. In 
general, while lithium levels <0.60 mmol/L appear not as effective as 
levels >0.60 mmol/L, there may be some patients for whom levels 
between 0.40 and 0.60 mmol/L are effective. Therefore, this may be 
an option for those who do not tolerate levels >0.60 mmol/L as well 
as for patients with impaired renal function or with increased risk 
of intoxication, for example, in the elderly (see below). In addition, 
levels <0.40 mmol/L do not seem to work at all. Therefore, there 
is no rationale for prescribing lithium at levels below 0.40 mmol/L.
Finally, the Nolen study also suggests no big additional benefit 
of levels 0.80 to <1.0 mmol/L over 0.60 to <0.85 mmol/L, which is 
in line with the Maj study which did not find a difference between 
levels 0.76‐0.90 mmol/L and 0.61‐0.75 mmol/L. Although we should 
recognize the possibility of a Type 2 error, for example, that with 
larger numbers a difference may have been found, these studies sug‐
gest an upper effective cutoff around 0.80 mmol/L. Nevertheless, 
again there may be some patients for whom higher levels up to 
1.00 mmol/L are more effective and well tolerated. In addition, 
however, there are no data supporting the notion that going beyond 
1.00 mmol/L is associated with any further benefit, possibly with 
exception of its use in the treatment of acute manic episodes (not 
further being discussed in this paper). In addition, the upper limit of 
0.80 or 1.00 mmol/L is of course also defined by the increased risk of 
side effects and toxicity at higher lithium serum levels.41
Taking all these above data into account, they do support the 
outcome of the Delphi survey: that for adults (18‐65 years) the stan‐
dard therapeutic lithium serum level in the maintenance treatment 
of bipolar disorder should be 0.60‐0.80 mmol/L with the option to 
reduce the level to the low therapeutic level of 0.40‐0.60 mmol/L 
in case of sufficient response but poor tolerance or to increase the 
level to the high therapeutic level of 0.80‐1.00 mmol/L in case of 
insufficient response and good tolerance (Figure 2). The recommen‐
dation for the standard therapeutic level of 0.60‐0.80 mmol/L is 
in line with the NICE guideline,2 the RANZCP guideline,3 the BAP 
guideline5 and the “Lithiumeter 2.0”.16
4.3 | What is the best timing of blood sampling?
No study was found that addressed this question but most of the in‐
cluded studies followed the generally accepted recommendation to sam‐
ple blood 12 ± 1 hours after the last (ie evening) intake. There was also 
consensus on this practice among the Task Force members for patients 
taking lithium twice daily or taking lithium once daily in the evening. 
However, there was no consensus on whether to sample in the evening 
or in the next morning for patients taking lithium once daily in the morn‐
ing, a dosing schedule probably hardly applied in clinical practice.
4.4 | Should the recommendations be different for 
dosing once daily vs twice daily and for immediate 
release vs extended release formulations?
There is pharmacogenetic evidence that a total daily dose of lithium 
given once daily results in a 10%‐15% higher 12 ± 1 hours trough 
level than when given twice daily.42 Nevertheless, there was consen‐
sus among the Task Force members that one could follow the same 
recommendations for optimal lithium serum levels for both dosing 
strategies. Similarly, the members also agreed that the recommen‐
dations should be the same for different formulations (immediate 
release vs extended release).
An important clinical implication of this approach is that the rela‐
tive small changes in 12 ± 1 hours trough levels caused by changes in 
dosing schedule or lithium formulation, should not necessarily lead 
to adjustments of the aimed lithium levels. In the absence of solid 
evidence to support an alternative approach, this simple pragmatic 
approach is reasonable and also compatible with the likely intra‐in‐
dividual variations that inevitably occur with respect to subsequent 
lithium levels obtained with a stable dose. In this context, it should 
be born in mind that the average lithium level in a given individual 
with a constant renal function and a constant intake of fluid and so‐
dium entirely depends on the total daily dose.8
406  |     NOLEN Et aL.
4.5 | Should the optimal serum level be different 
for the prevention of manic (and mixed) episodes 
compared to depressive episodes?
While lithium is effective in the prevention of both manic and de‐
pressive episodes43 there is the question whether same lithium 
levels should be applied. The 4 studies (Waters, Maj, Vestergaard, 
Nolen) that addressed this issue did not find evidence that lithium 
serum levels for the prevention of specific episodes should be dif‐
ferent than for other episodes. In the Delphi survey there was only 
consensus that the recommendations for the prevention of mixed 
episodes should be the same as for the prevention of manic epi‐
sodes. The recommendations for other comparisons (ie manic vs 
depressive episodes; hypomanic vs manic episodes; subsyndromal 
depressive vs depressive episodes) did not result in consensus, al‐
though the majority of members supported the statements that the 
levels should be the same for the prevention of all types of episodes.
4.6 | Should recommendations take ethnicity or 
gender into consideration?
We did not find any study addressing these topics in relation to op‐
timal lithium serum levels. Therefore, we also did not formulate rec‐
ommendations on these issues.
A specific group concerns pregnant women. Pregnant women 
can be treated with lithium, but the recommendations in this paper 
are not applicable for them. For more specific information, we refer 
to a recent paper by Wesseloo et al.44
4.7 | Should recommendations for children and 
adolescents or for elderly patients be different 
from the recommendations for (younger) adults?
Two of the selected studies (Coppen, Vestergaard) did not provide 
information on whether they had included patients below 18 years 
or above 65 years and 2 other studies did not include patients below 
18 years or above 65 years (Waters, Maj). The remaining 3 studies 
did only include patients above 18 years including elderly patients, 
but did not provide separate information on the outcome of the 
elderly patients. Thus, we can conclude that evidence on optimal 
lithium serum levels in children, adolescents and the elderly (see also 
Ref. 38) is lacking.
This is also reflected by outcome of the Delphi survey regarding 
the endorsement of the statements on optimal lithium serum lev‐
els in the various age groups of which only the statement on adults 
(18‐65 years) was endorsed by at least 80% (in consensus) of the Task 
Force members. However, for all age groups there was consensus 
that the minimum effective lithium level for all age groups should be 
0.40 mmol/L, while in adults the standard therapeutic level should be 
between 0.60 and 0.80 mmol/L within a broader range of 0.40‐1.00 
(Figure 2). For children (<12 years) and adolescents (12‐17 years) 
there was no consensus, but the majority of the Task Force members 
endorsed the same recommendation as for adults (see also Figure 2). 
For the elderly there was also no consensus. However, the majority 
of the members endorsed the recommendation that the standard 
therapeutic level should be 0.40‐0.60 mmol/L, with the option to go 
to maximally 0.70 of 0.80 mmol/L in elderly 65‐79 years and to max‐
imally 0.7 mmol/L in elderly 80 years and older (Figure 3), which is 
in line with the recommendations on the use of lithium in the elderly 
from the ISBD Task Force on Older Adults with Bipolar Disorder: 
that although “the balance between lithium toxicity and efficacy has 
not been studied in older patients and the recommendations are mainly 
based on clinical judgement and fear of drug‐related adverse events”,38 
the upper limit should be lower than in younger adults.45
4.8 | Practical considerations regarding lithium 
level monitoring
Due to lithium's low therapeutic index, its serum levels should al‐
ways be monitored during treatment, at least when treatment is 
initiated, after each dose increase and every 3‐6 months thereafter. 
The blood samples for measuring the lithium level must be drawn at 
F I G U R E  2   Recommendation for 
optimal lithium serum levels in the 
maintenance treatment of bipolar 
disorder: endorsed in consensus by the 
Task Force members for adults (18‐65 y) 
and by the majority of the members 
for children (<12 y) and adolescents 
(12‐17 y) [Colour figure can be viewed at 
wileyonlinelibrary.com]
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steady state occurring after 5‐6 times the half‐life of lithium, which 
is approximately 24 hours in the nonelderly with normal renal func‐
tion. Thus, the lithium level should be measured after 5‐6 days at 
constant daily dosing. In the elderly or in patients with impaired 
renal function, the time to steady state increases, implying that 
the lithium level should also be measured after 10‐12 days. In in‐
dividual patients treated with a given schedule with a given lithium 
formulation, at steady state, the ratio of daily lithium dose, and the 
12 hours lithium level is constant. An additional requirement for 
safe use of lithium is to monitor renal function at baseline and also 
every 3‐6 months.
Finally, it should be taken into account that subjects with a rela‐
tively high renal function, in particular young men, may have an un‐
expectedly low 12‐hours lithium level despite a relatively high daily 
lithium dose due to relative large variations in lithium levels over the 
day. If the dose is increased to obtain a lithium level within the rec‐
ommended range, such patients may become intoxicated.46
5  | CONCLUSION
Based on our review and the responses obtained in our Delphi 
survey we recommend that the standard serum level in the main‐
tenance treatment of adults with BD should be 0.60‐0.80 mmol/L 
with the option to reduce the level to 0.40‐0.60 mmol/L in case of 
sufficient response but poor tolerance, or to increase the level to 
0.80‐1.00 mmol/L in case of insufficient response and good toler‐
ance. For children and adolescents the majority of the Task Force 
members endorsed the same recommendation, while for the el‐
derly the majority endorsed a more conservative approach: usu‐
ally 0.40‐0.60 mmol/L, with the option to go to maximally 0.70 or 
0.80 mmol/L at ages 65‐79 years, and to maximally 0.70 mmol/L 
over age 80 years. Sampling should be in the morning 12 ± 1 hours 
after intake of the evening dose. Tentative recommendations for 
optimal serum lithium levels should be the same with once and twice 
daily dosing, and with immediate release formulations compared to 
extended release formulations.
While the above recommendations reflect the available evi‐
dence, more high‐quality research is still needed to provide more 
refined advices.
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